This study will be restricted to all original articles of healthy adults (people not suffering from any diseases). We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
KAGOME CO., LTD.
Review Team Mr. Takuro Inoue, Innovation Division, KAGOME CO., LTD. Mr. Kazutaka Yoshida, Innovation Division, KAGOME CO., LTD. Mr. Yudai Aoki, Innovation Division, KAGOME CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled trials (RCT), quasi randomized controlled trials (qRCT), non-randomized controlled trials (nonRCT), crossover trials, cohort studies, and case-control studies. We will include scientific papers and reports which give us enough research details. (PICO) Participant: We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Intervention: We define oral intake of Lactobacillus brevis KB290 as an intervention. Comparison: We define oral intake of test food not containing Lactobacillus brevis KB290 or maintaining daily life as controls. Outcome measurement: We will evaluate bowel movement frequency as primary outcome. We will evaluate the number of Lactobacillus group and Bifidobacterium genus in stool sample, concentration of organic acids (total organic acid, acetic acid, propionic acid) in stool sample, and feeling after defecation as secondary outcomes. (PECO) Participant: We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Exposure: We define oral intake of Lactobacillus brevis KB290 as an exposure. Comparison: We define eating no food containing Lactobacillus brevis KB290 as non-exposure. If subgroup analysis of Lactobacillus brevis KB290 intake amount has been conducted in a study, we define the least intake group as a non-exposure group. Outcome measurement: We will evaluate bowel movement frequency as primary outcome. We will evaluate the number of Lactobacillus group and Bifidobacterium genus in stool sample, concentration of organic acids (total organic acid, acetic acid, propionic acid) in stool sample, and feeling after defecation as secondary outcomes. (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude cross-sectional studies because it will be difficult to interpret causal relationships between exposure and outcome. We will also exclude proceedings and unpublished studies which don't give us enough research details.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of Lactobacillus brevis KB290 intake on bowel movement frequency. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will evaluate of the effects of Lactobacillus brevis KB290 intake on the number of Lactobacillus group and Bifidobacterium genus in stool sample, concentration of organic acids (total organic acid, acetic acid, propionic acid) in stool sample, and feeling after defecation. | — |
Countries
Japan
Contacts
Public ContactKoichi Aizawa
KAGOME CO., LTD. Innovation Division
Outcome results
None listed